The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | hAd5 |
Manufacturing
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa
ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.
History
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials. The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."
Clinical trials
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.
References
- ^ "ImmunityBio Inc: hAd5-Covid-19 â COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 23 March 2021.
- "SA's Biovac to team up with US based ImmunityBio in making its vaccine". BusinessInsider. Retrieved 23 March 2021.
- ^ "Covid-19 to Serve as Platform for South African Vaccine Industry". Bloomberg.com. 19 March 2021. Retrieved 20 March 2021.
- Fisher S. "Nzimande excited about vaccine partnership between Biovac & ImmunityBio". ewn.co.za. Retrieved 20 March 2021.
- Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 20 March 2021.
- Cross R (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
- ^ Cohen J (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
- "ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread". www.businesswire.com. 19 January 2021. Retrieved 23 March 2021.
- Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 23 March 2021.
External links
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
